The Centers for Disease Control and Prevention (CDC) announced its Traveler-Based Genomic Surveillance (TGS) program has exceeded one million voluntary participants, enhancing the U.S.’s capacity to detect emerging public health threats. The program collects anonymous nasal samples from international travelers at select airports and analyzes wastewater to monitor pathogens. Launched in 2021, TGS focuses on early detection of respiratory virus variants and other infectious agents. It reported the first detections of influenza H3N2 subclade K seven days before global reports, highlighting its role in rapid biosurveillance. The initiative operates through public-private partnerships with organizations like Ginkgo Biosecurity and XWell, as well as U.S. airports. CDC Director Jim O’Neill emphasized the program’s value in safeguarding the nation using domestic tools. Participation remains voluntary, with over 2,600 wastewater samples analyzed alongside traveler data.
Source: Centers for Disease Control and Prevention (CDC).
Materials developed by CDC.
This content is available on the CDC website at no charge.
Use of this material does not imply endorsement by the CDC, the Department of Health and Human Services, or the U.S. Government.
https://www.cdc.gov/media/releases/2026/2026-cdc-surpasses-1-million-voluntary-air-travel-participants-in-biosurveillance-program.html
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.